US Pharmaceutical GMP Readiness: Making 21 CFR 211 Visible in Records
The quality unit approves or rejects everything, and every unexplained discrepancy is investigated. Your records should show both.
In Short
- Quality unit approves or rejects.
- Investigate even distributed batches.
- Keep records 1 year past expiry.
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.
- Who decides, and who may not
- Supplier to finished bulk
- Test, review, investigate
We ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.
21 CFR 211.22 gives the quality control unit authority to approve or reject components, containers, closures, in-process materials, packaging, labeling and drug products, and 211.192 requires a thorough investigation of any unexplained discrepancy or specification failure found in production and control record review. Readiness means your records show both, batch by batch.
Written Procedures, Followed
Production and process control procedures are written, approved by the quality unit and followed, with deviations recorded and justified (211.100). An approved master record is the start point for each batch record (211.186 and 211.188).
Investigations
Any unexplained discrepancy, or the failure of a batch or any of its components to meet its specifications, is thoroughly investigated, whether or not the batch has already been distributed (211.192). The investigation extends to other batches of the same drug product and other drug products that may have been associated with the failure or discrepancy, and a written record includes the conclusions and follow-up.
Worked Example: a Yield Discrepancy
- Day 0Batch TB-552 yield below the master record minimumProduction
- Day 1Investigation opened; prior batches on the same line checkedQuality
- Day 5Cause recorded; corrective action assignedQuality
- Day 6Quality unit decision on the batch recordedQA
Complaints
Written procedures cover all written and oral complaints, including quality unit review of any complaint about a possible failure to meet specifications and a decision on whether to investigate under 211.192 (211.198(a)). When no investigation is conducted, the record states the reason and the responsible person who decided (211.198(b)(3)).
More on complaints
The complaint record identifies the lot where known.
Retention and a Practical Check
Batch production, control and distribution records are kept at least 1 year after the batch's expiration date; for certain OTC drug products without expiration dating because they meet the § 211.137 exemption, 3 years after distribution of the batch (211.180(a)). Test readiness by picking one batch and showing its master record, executed record, investigations, complaints and release decision together.
More on retention and a Practical Check
The GMP manufacturing readiness guide walks that batch in detail, and the 21 CFR Part 211 drug CGMP guide explains the underlying control chain.
Questions
Who approves or rejects drug products?
The quality control unit (21 CFR 211.22(a)).
Must distributed batches be investigated?
When there is an unexplained discrepancy (including a yield outside the master record's limits) or a failure to meet specifications, yes: 211.192 requires the investigation whether or not the batch has already been distributed, extended to other batches and drug products that may be associated.
How long are batch records kept?
At least 1 year after the batch expiration date (211.180(a)); for certain OTC products lacking expiration dating under the § 211.137 exemption, 3 years after distribution of the batch.
Does software make a site GMP compliant?
No. Under Part 211 the quality control unit approves or rejects and reviews records; software can hold the records, but people run the procedures and make release decisions.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
